Tear Film Markers in Dry Eye Syndrome

Withdrawn before enrolling · Phase 4

Conditions studied: Dry Eye

In brief

Dry eye is the most common reason for visit to an ophthalmologist's office. The prevalence is on the rise and is mainly attributed to factors such as increased environmental pollution and contact lens use. The current management options are limited to over the counter artificial tear drops and three FDA-approved drugs. Of these, cyclosporine has been used worldwide for treating mild to moderate dry eyes. The earlier version consisted of 0.05% cyclosporine which worked well for a limited number of inflammatory dry eye conditions. Recently, 0.09% cyclosporine was approved by the FDA. The nearly double concentration is expected to be more beneficial for severe inflammation which is often seen in Sjögren syndrome and other Rheumatological conditions associated with dry eyes. In this pilot project, the investigator proposes to evaluate the change in expression of SLURP1 and other markers of ocular surface inflammation before and after treatment with 0.09% cyclosporine eye drops.

Key facts

Study ID

NCT04515329

Run by

Vishal Jhanji

People needed

0

Starts

2023-12-08

Expected to finish

2023-12-08

Last updated by the study team

2023-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with Dry Eye, but who have not been prescribed a drug to treat this condition.
• 18 years of age and older
• OSDI score > 12

You may not qualify if…

• Younger than 18 years of age.
• Any other associated eye diseases other than Dry Eye.
• Inability to understand and give informed consent.
• Patients diagnosed with Dry Eye who are already using Cequa.

Where it is running

• UPMC Eye Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.